FMC Corporation reported its financial results for the second quarter of 2025, showing a slight increase in revenue and a significant drop in net income. The company recorded revenue of $1.051 billion, marking a 1% rise from $1.038 billion in Q2 2024. However, FMC's GAAP net income plummeted by 77% to $67 million, down from $295 million in the same quarter of the previous year. This decline was attributed to gains related to tax incentives recorded in the prior year. The adjusted EBITDA increased by 2% to $207 million, representing 19.7% of revenue, compared to $202 million or 19.4% of revenue in Q2 2024. Adjusted EPS rose by 10% to $0.69 from $0.63. The company noted a 2% organic growth in revenue, driven by strong cost favorability and high-single-digit growth in its portfolio sales, particularly from new active ingredients. FMC also faced FX headwinds affecting sales and EBITDA and a lower price due to adjustments in "cost-plus" contracts with diamide partners. FMC announced that it is in the process of selling its India commercial business, though it will continue to supply the buyer with its IP-protected products and retain global manufacturing operations in India, with the sale anticipated within the next year.